Crossmark

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease

Published Online: 2019-05-21

Authors

Uehara, Takuya

Choong, Chi-Jing

Nakamori, Masayuki

Hayakawa, Hideki

Nishiyama, Kumiko

Kasahara, Yuuya

Baba, Kousuke

Nagata, Tetsuya

Yokota, Takanori

Tsuda, Hiroshi

Obika, Satoshi https://orcid.org/0000-0002-6842-6812
Mochizuki, Hideki https://orcid.org/0000-0002-0874-7542
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)

Japan Agency for Medical Research and Development (18ek0109195h0003)
License Information

Text and Data Mining valid from 2019-05-21

Version of Record valid from 2019-05-21
More Information

Article History

Received: 12 October 2018

Accepted: 25 April 2019

First Online: 21 May 2019

Competing Interests

: The authors declare no competing interests.

Document is current